Issue Date: August 20, 2007
Pharma's Mixed Bag
AS ILLUSTRATED BY A WIDE RANGE of second-quarter results, the pharmaceutical industry's reliance on "blockbuster" drugs is a double-edged sword. Although Pfizer and GlaxoSmithKline were taken down a notch by pressures on multi-billion-dollar drugs, Merck and Schering-Plough are at their healthiest in years thanks to skyrocketing sales . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society